Skip to main content
Figure 1 | Cardiovascular Diabetology

Figure 1

From: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

Figure 1

a&b: Risk factor distribution (Figure 1a) and presence of metabolic risk factors in patients with or without the metabolic syndrome (Figure 1b). Fasting plasma glucose 110 mg/dL; Abdominal obesity > 102 cm in men/> 88 cm in women; Triglycerides ≥ 150 mg/dL; Blood Pressure ≥ 130/≥ 85 mmHg; HDL cholesterol: < 40 mg/dL in men, < 50 mg/dL in women; Met (+) – Patients with the metabolic syndrome (doctors diagnosis); Met (-) – Patients without the metabolic syndrome; statistical test applied: Chi2-test

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840